Regeneron’s FOP Drug Garetosmab Secures FDA Priority Review

FOP is a devastating condition where bone forms abnormally in muscles, tendons, and ligaments, eventually leading to severe immobility. According to Regeneron, garetosmab is the first investigational therapy demonstrated to reduce both the number and volume of these new heterotopic bone lesions in adult patients. If authorized, it would become the only available treatment specifically targeting this mechanism of the disease.

Regulatory Timeline and Clinical Expansion

The FDA’s decision to grant priority review underscores the urgent need for therapeutic options in the FOP space. The agency reserves this status for medicines that offer significant improvements over existing standards of care for serious conditions. Regeneron confirmed the FDA has set a target action date in August to complete its evaluation.

Beyond the adult population, the Tarrytown, N.Y.-based biotechnology firm is preparing to expand its clinical program. The company plans to initiate a Phase 3 study of garetosmab in adolescents and children with FOP later this year. This expansion follows positive data suggesting the drug's potential to alter the trajectory of the disease before it causes irreversible physical damage.